MIJ821 (onfasprodil) in healthy volunteers: First‐in‐human, randomized, placebo‐controlled study (single ascending dose and repeated intravenous dose).

Autor: Gomez‐Mancilla, Baltazar^1,2 (AUTHOR), Levy, Jeffrey A.³ (AUTHOR), Ganesan, Subramanian⁴ (AUTHOR), Faller, Thomas¹ (AUTHOR), Issachar, Gil⁵ (AUTHOR), Peremen, Ziv⁵ (AUTHOR), Laufer, Offir⁵ (AUTHOR), Shani‐Hershkovich, Revital⁵ (AUTHOR), Biliouris, Kostas⁶ (AUTHOR), Walker, Ela¹ (AUTHOR), Healy, Mark P.⁶ (AUTHOR) mark.healy@novartis.com, Sverdlov, Oleksandr⁷ (AUTHOR), Desai, Sachin⁷ (AUTHOR), Ghaemi, S. Nassir^6,8 (AUTHOR), Cha, Jang‐Ho⁶ (AUTHOR), Shanker, Y. Gopi^6,9 (AUTHOR)

Publikováno v: CTS: Clinical & Translational Science. Nov2023, Vol. 16 Issue 11, p2236-2252. 17p.

Efficacy and safety of mij821 in patients with treatment-resistant depression: Results from a randomized, placebo-controlled, proof-of-concept study

Autor: N. Ghaemi, A. Sverdlov, R. Shelton, R. Litman

Publikováno v: European Psychiatry, Vol 64, Pp S334-S335 (2021)

Introduction MIJ821 is a novel N-methyl-D-aspartate (NMDA) receptor antagonist, with a potentially low rate of the psychotomimetic side effects that limit the therapeutic utility of ketamine in treatment-refractory depression (TRD). Objectives To a

Externí odkaz: https://doaj.org/article/762925064b344c5ca28fc595ac94f1b9

New Clinical Trials and Studies Findings from Novartis Institutes for Biomedical Research Described [Mij821 (Onfasprodil) In Healthy Volunteers: First-in-human, Randomized, Placebo-controlled Study (Single Ascending Dose and Repeated Intravenous...].

Publikováno v: Clinical Trials Week; 11/14/2023, p1357-1357, 1p

Cadent Therapeutics Receives Milestone Payment for Initiation of Phase 2 Trial of MIJ821 in Treatment-Resistant Depression

Autor: Cadent Therapeutics

Publikováno v: Business Wire (English). 05/23/2019.

Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline.

Autor: Masson, Gabrielle (AUTHOR)

Publikováno v: FierceBiotech. 10/10/2023, pN.PAG-N.PAG. 1p.